Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Iselin, NJ, US. The stock last traded at $1.15, up 1.33% on the session, giving a market capitalisation of $214.1M. On trailing twelve-month figures it carries a trailing P/E of -0.84, a net margin of -18297.5%. Its beta of 0.80 implies it has historically moved less than the broad market.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Outlook Therapeutics, Inc. is most often compared with the following Healthcare names: